说明：双击或选中下面任意单词，将显示该词的音标、读音、翻译等；选中中文或多个词，将显示翻译。
您的位置：首页 -> 词典 -> 尿激酶型纤溶酶原激活物
1)  urokinase-type plasminogen activator
尿激酶型纤溶酶原激活物
1.
Urokinase-type plasminogen activator with its inhibitor and liver fibrosis;
尿激酶型纤溶酶原激活物及其抑制物与肝纤维化
2.
Relationship between the prognosis of chronic severe hepatitis and the expression of urokinase-type plasminogen activator;
尿激酶型纤溶酶原激活物的表达与慢性重型肝炎预后的相关性
3.
Clinical significance of urokinase-type plasminogen activator system in patients with malignant tumor of digestive tract;
消化道肿瘤患者血浆尿激酶型纤溶酶原激活物系统的变化及其意义
更多例句>>
2)  uPA
尿激酶型纤溶酶原激活物
1.
Expression of osteopontin and uPA in gastric carcinoma tissue;
胃癌组织中骨桥蛋白与尿激酶型纤溶酶原激活物的表达
2.
The Expression of uPA and Endostatin in Human Colorectal Carcinoma and Their Relations to Angiogenesis;
人大肠肿瘤中尿激酶型纤溶酶原激活物和内皮抑素的表达与血管新生的关系
3.
Objective To explore the expression of nuclear factor kappa B(NF-κB) and urokinase-type plasminogen activator(uPA) in human cerebral gliomas and their effect on the invasive growth and malignant development of human cerebral glioma.
目的研究人脑胶质瘤中核转录因子-κB(NF-κB)和尿激酶型纤溶酶原激活物(uPA)的表达,探讨二者在胶质瘤侵袭性生长和恶性进展中的作用。
更多例句>>
3)  urokinase type plasminogen activator
尿激酶型纤溶酶原激活物
1.
The purpose of this article is to study the effects of pro-urokinase on the expression and release of urokinase type plasminogen activator receptor(u-PAR) and plasminogen activator inhibitor1(PAI-1) and to study the effects of pro-urokinase on the mR.
目的探讨重组尿激酶原对体外培养的正常人肺动脉内皮细胞(HPAECs)尿激酶型纤溶酶原激活物系统表达的影响。
2.
Objective To explore the effects of urokinase type plasminogen activator(uPA) gene-modified bone marrow-derived stem cells(BDLSCs) transplantation on CCl4-induced liver fibrosis in rats.
目的探讨尿激酶型纤溶酶原激活物(uPA)基因修饰骨髓源性肝干细胞(BDLSC)移植对四氯化碳(CCl4)诱导的大鼠肝纤维化的影响。
3.
This paper is to study the significance of urokinase type plasminogen activator (uPA) expression in non small cell lung cancer (NSCLC).
采用免疫组织化学 (S- P)法对 37例非小细胞肺癌组织中的尿激酶型纤溶酶原激活物 (urokinase- type plasminogenactivator,u PA)进行检测、分析。
更多例句>>
4)  Urinary plasminogen activator
尿激酶型纤溶酶原激活物
例句>>
5)  urokinase-type plasminogen activator(uPA)
尿激酶型纤溶酶原激活物
1.
Objective To investigate the relationship between plasma level of urokinase-type plasminogen activator(uPA),urokinase-type plasminogen activator receptor(uPAR)and plasminogen activator inhibitor type 1(PAI-1)and ovarian cancer.
目的探讨尿激酶型纤溶酶原激活物(uPA)及其受体(uPAR)和抑制剂(PAI-1)血浆含量与卵巢恶性肿瘤之间的关系。
2.
OBJECTIVE: To investigate the expression of urokinase-type plasminogen activator(uPA)andβ-catenin proteins and their relations with tumor angiogenesis and explore their correlation with invasion and metastasis of thyroid carcinoma.
目的 研究甲状腺癌组织中尿激酶型纤溶酶原激活物(uPA)、β-连环素蛋白表达及其与血管生成的关系，探讨其在甲状腺癌侵袭、转移中的作用。
更多例句>>
6)  urokinase-type plasminogen activator
尿激酶纤溶酶原激活物
1.
Aim: To investigate the expression of urokinase-type plasminogen activator (uPA) in human colorectal carcinoma tissue and its relation to the neovascularization.
目的检测大肠癌组织中尿激酶纤溶酶原激活物(uPA)及微血管密度(MVD)。
2.
The protein level of urokinase-type plasminogen activator (uPA) was also determined by western blotting.
采用Western blot方法检测癌细胞尿激酶纤溶酶原激活物(uPA)蛋白水平。
3.
Besides,the protein level of urokinase-type plasminogen activator(uPA) was also determined by Western blot assay.
另外,采用Western blot方法检测癌细胞尿激酶纤溶酶原激活物(urokinase-type plasminogen activator,uPA)蛋白变化。
补充资料：乙酰化纤溶酶原-链激酶激活剂复合物
药物名称：乙酰化纤溶酶原-链激酶激活剂复合物

英文名：APSAC

该药对血块有选择性高亲和力且半衰期长，清除半衰期为70分钟，故纤维蛋白溶解作用缓慢而持久。用药后5-8小时仍可维持有效溶栓血药浓度，有报告作用维持7-10天，而SK用药后3小时血中即完全清除，因此可视为长效SK。

APSAC用药特点是短RV间内一次给予全部剂量。据报告冠状动脉内溶栓5分钟内注射5-30mg，1-4小时后闭塞动脉再通率为70-83％。静脉给药5分钟内注入5-30mg，再通率为60-100％。该药全身纤溶作用微弱，用药简单，药物作用时间长，然而再闭塞率可达20％，但平均再闭塞率仍较SK、rt-PA为低。


类别：溶栓药
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条